ValuentumAd

Official PayPal Seal

Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Sep 28, 2015
Biotechs Bruised
If one is gambling on the drugs of the future, then one must also deal with the uncertainties of the present. Regulatory risk has taken the air out of the biotech space.
Aug 13, 2015
Big Pharma Earnings Continued…
Amgen, AstraZeneca, Merck, and Pfizer...
Aug 7, 2015
The Great Pipeline Cash Flow Deficiency
Investors simply don’t know the quality of the assets in the ground, and the operators’ financials aren’t much to speak of in light of much safer dividend growth opportunities elsewhere.
Jul 28, 2015
Quick Take: Gilead Blows By 2Q Estimates; Investors Getting Drug Pipeline for Free
We continue to like the company that found a way to cure hepatitis C.
Jul 26, 2015
Dividend Increases for the Week Ending July 24
Let's take a look at companies raising their dividends this week.
Jul 23, 2015
Guide to Second Quarter Earnings; Big Pharma Experiencing Earnings Momentum
Abbott, Bristol-Myers, Celgene, Eli Lilly, Novartis, Roche, Valeant…
Jul 21, 2015
Higher Maintenance Costs for Pipelines?
Plains All American Pipeline has garnered national attention with two pipeline spills in the past two months. Let’s take a look at the reasons behind Plains All American Pipeline’s infrastructure problems.
Jul 17, 2015
J&J’s Quarterly Results Not Reflective of Underlying Strength
On the surface, Johnson & Johnson’s second-quarter results weren’t that great, but let’s take a closer look at the performance.
Jul 10, 2015
Creditor Risk Aversion Rises Considerably in Energy, Metals & Mining Sectors
In a recent Moody’s ‘Capital Markets Research’ report, according to a tabulation performed by Credit Suisse, bond spreads have widened an incredible 385 basis points for high-yield metals/minerals companies and 367 basis points for energy companies in the one-year period ending July 8, 2015. We continue to underweight these sectors within the newsletter portfolios. Creditor risk aversion continues to swell in these two sectors, and the worst has yet to come, in our view.
Jun 16, 2015
Target-CVS Agreement: What It Really Means
Target and CVS recently signed a major partnership, but a Best Ideas Newsletter portfolio holding may benefit the most from the agreement. Let’s take a closer look at effects of the deal.



The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.